Skip to contentP
Perspective Therapeutics, Inc.
P
CATXPerspective Therapeutics, Inc. Q3 2023 · 10-Q
Revenue$2.19M$2.19M+27.3% vs Q3 2022 Net Income-$10.36M-$10.36MN/M vs Q3 2022 EPS Diluted-$0.37-$0.37no prior Q3 2022 on file Gross Profit$738,000+78.3% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Perspective Therapeutics, Inc. · CIK 728387 · Engraved from SEC EDGAR
Operating Cash Flowderived-$10,110,000N/M Free Cash Flowderived-$10,337,000N/M Margins · derivedGross margin33.8%+9.7 pt vs Q3 2022
Operating margin-446.2%−201.1 pt vs Q3 2022
Net margin-474.0%−237.0 pt vs Q3 2022
ended Sep 30, 2023 · filed Nov 14, 2023 · 45 d after period end